1. Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Altogen labs
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Altogen Biosystems offers the LNCAP Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits.
The LNCAP Transfection Reagent is a nanoparticle-based liposome formulation, and it has been developed to provide high transfection efficiency with the LNCAP cell line.
This cell line is a good host for studying prostate and hormone functions. When cultured in vitro, LNCAP cells are a monolayer and adhere to the surface of the culture flask.
Other applications include drug discovery, gene expression studies, molecular and cell biology research applications.
Purchase LNCAP Transfection Kit at
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

2. High Density LNCAP cells
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
LNCAP Cell Line Description and Applications
The LNCaP cell line originates from a metastatic site of human prostate adenocarcinoma cells. The cell line was derived in 1977 from the supraclavicular lymph node of a 50-year old Caucasian male. The LNCaP cell line can grow as both a single cell or in aggregate form and displays adherent epithelial morphology. The cell line is also receptive to hormones and has a high affinity for androgen receptors and nuclear fractions of cells. Furthermore, the cytosol contains estrogen receptors. The LNCaP also produces Prostate Specific Antigen. Research with hormonal manipulations indicates that tumor development correlates with serum androgen levels. This cell line is hypotetraploid, and the modal chromosome number is 84.
High Density LNCAP cells
Atcc.org
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

3. LNCAP Transfection Protocol
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Protocol
1. Plate 10, ,000 LNCAP cells per well in 0.5 ml of complete growth medium 12–24 hours prior to transfection
2. Wash with 1xPBS and add 0.5 ml of fresh growth medium
3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent, and
• 750 ng DNA (or mRNA), or
• 30 nM - 50 nM of siRNA (or microRNA)
*Referred to a final volume including growth medium
4. Incubate transfection complexes at RT for minutes
5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex, therefore increasing transfection efficiency; however, it may increase cell toxicity
6. Add prepared transfection complexes to 0.5 ml of complete growth medium with LNCAP cells (from step 2)
7. Incubate cells at 37ºC in a humidified CO2 incubator
8. Assay for phenotype or target gene expression hours after transfection
Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of Transfection Enhancer reagent hours after transfection
If the viability of LNCAP cells being transfected is affected at hours post-transfection, the level of cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

4. General Lipoplex-mediated Transfection Mechanism of Action
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
General Lipoplex-mediated Transfection Mechanism of Action
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

5. LNCAP Transfection Kit Product Details
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Kit Product Details
A nanoparticle-based liposome formulation
Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNA
Transfection Enhancer reagent provided with the kit
Produce higher level of recombinant protein expression with minimal disruption of normal cell function
Generate physiologically relevant data you can trust
Effective for plasmid DNA/siRNA co-transfection
Easy-to-use transfection protocol with reproducible results
Low cytotoxicity
Developed and manufactured by Altogen Biosystems (
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   

6. Data Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Data
Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into LNCaP cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).

7. Data Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Data
Figure 2. Protein expression of Lamin A in LNCAP cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into LNCAP cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

8. LNCAP Transfection Kit Benefits
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
LNCAP Transfection Kit Benefits
Pre-optimized transfection protocol for LNCAP cell line
Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing
Free of serum and protein of animal origin
Compatible with standard and reverse transfection methods (both protocols provided in the kit manual)
Easy to use LNCAP transfection protocol ensures great performance with expedited experimental timeline
Equally efficient for single or multiple transfections
Can be used for transient transfection and development of stable LNCAP cell lines
Bio-degradable after endocytosis
Used for preclinical research worldwide
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA
Telephone   Fax   